1-20 of 40
Kenneth C. Anderson
Close
Sort by
Articles

ASH's Research Agenda Gets a Tune-Up

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2017) 14 (6)
https://doi.org/10.1182/hem.V14.6.7920
Published: 2017
Articles

Staying Vigilant on Health Care Reform

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2017) 14 (5)
https://doi.org/10.1182/hem.V14.5.7649
Published: 2017
Articles

Beyond Business As Usual

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2017) 14 (4)
https://doi.org/10.1182/hem.V14.4.7511
Published: 2017
Articles

Standing Up for Patients

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2017) 14 (3)
https://doi.org/10.1182/hem.V14.3.7317
Published: 2017
Articles

Way to Make a Statement: Government Policy and ASH

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2017) 14 (2)
https://doi.org/10.1182/hem.V14.2.7176
Published: 2017
Articles

Motivation for Education

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2017) 14 (1)
https://doi.org/10.1182/hem.V14.1.7012
Published: 2017
Articles

Oral Proteasome Inhibitors in Multiple Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2012) 9 (6)
https://doi.org/10.1182/hem.V9.6.1104
Published: 2012
Articles

Lenalidomide Maintenance Therapy in Multiple Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2012) 9 (5)
https://doi.org/10.1182/hem.V9.5.1132
Published: 2012
Articles

Microenvironment-Induced Genomic Instability in Multiple Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2012) 9 (4)
https://doi.org/10.1182/hem.V9.4.1144
Published: 2012
Articles

The Added Value of 18-F FDG PET/CT in Defining Prognosis and Response in Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2012) 9 (3)
https://doi.org/10.1182/hem.V9.3.1166
Published: 2012
Articles

Delineating Molecular Mechanisms of Proteasome and Histone Deacetylase Inhibitor-Induced Myeloma Cytotoxicity

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2012) 9 (2)
https://doi.org/10.1182/hem.V9.2.1178
Published: 2012
Articles

Combined Histone Deacetylase and Proteasome Inhibitor Therapy in Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2012) 9 (1)
https://doi.org/10.1182/hem.V9.1.1194
Published: 2012
Articles

Multiple Myeloma: To T or Not to T, What Will the Answer Be?

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2011) 8 (6)
https://doi.org/10.1182/hem.V8.6.1204
Published: 2011
Articles

Can We Treat Myeloma at Early Stages?

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2011) 8 (5)
https://doi.org/10.1182/hem.V8.5.1228
Published: 2011
Articles

Sequencing the Myeloma Genome

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2011) 8 (4)
https://doi.org/10.1182/hem.V8.4.1256
Published: 2011
Articles

Induction Combination Novel Agent Therapies in Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2011) 8 (3)
https://doi.org/10.1182/hem.V8.3.1268
Published: 2011
Articles

Clinical Anti-Myeloma Activity of Aminobisphosphonates

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2011) 8 (2)
https://doi.org/10.1182/hem.V8.2.6308
Published: 2011
Articles

How is Bortezomib Best Used in Myeloma?

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2011) 8 (1)
https://doi.org/10.1182/hem.V8.1.6312
Published: 2011
Articles

Role of Allotransplantation in Myeloma

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2010) 7 (6)
https://doi.org/10.1182/hem.V7.6.6274
Published: 2010
Articles

A Step Toward Safer Immunomodulatory Drugs

Kenneth C. Anderson, MD
Journal: The Hematologist
The Hematologist (2010) 7 (5)
https://doi.org/10.1182/hem.V7.5.6233
Published: 2010